Abstract:Background Anti-angiotensin II receptor subtype 1 (AT1 receptor) autoantibodies have previously been shown in sera of hypertensive patients. This study assessed whether anti-AT1-receptor autoantibody in serum is correlated with the efficacy of an AT1-receptor blocker (ARB; candesartan)-based regimen in hypertensive patients after 8 weeks of treatment.Design The Study of Optimal Treatment in Hypertensive Patients with Anti-AT1-Receptor Autoantibodies is a multicentre, randomised, blinded endpoint, open-label, parallel-group comparison clinical trial conducted in five centres in Wuhan, China. Treatment is designed as stepwise added-on therapy to reduce blood pressure (BP) < 140/90 mm Hg. 512 patients with moderate to severe primary hypertension were randomly assigned to an 8-week treatment with either ARB (candesartan)based regimen (n=257) or ACE inhibitor (imidapril)based regimen (n=255).Results Systolic and diastolic BP was reduced significantly in both treatment groups. The candesartan-based regimen achieved a significantly greater systolic BP reduction than imdapril (30.8+/-10.3 vs 28.8+/-10.3 mm Hg, p=0.023). In those anti-AT1 receptor autoantibody-positive hypertensive patients, the mean systolic BP at baseline was higher than in the anti-AT1 receptor autoantibody-negative group (160.5+/-16.5 vs 156.2+/-17.7 mm Hg; p=0.006). The mean BP reduction was greater in the candesartan-based regimen than the imidapril-based regimen (-35.4+/-9.8/16.9+/-6.9 vs -29.4+/-9.8/14.2+/-6.9 mm Hg; p=0.000 and 0.002, respectively), and more patients on imidapril required add-on medications to achieve BP control (94% vs 86%; p=0.03). No correlation was observed between the titre of anti-AT1 receptor autoantibody and the efficacy of candesartan-based therapy. In those anti-AT1 receptor autoantibody-negative patients similar BP lowering was reached in the candesartan and the imidapril-based regimens.Conclusions An ARB-based regimen is more effective in BP lowering than an ACE inhibitor-based regimen in the presence of anti-AT1 receptor autoantibodies.

Efficacy and Safety of the Compound of Candesartan Cilexetial and Hydrochlorothiazide in Patients with Essential Hypertension

Clinical Study of Olmesartan/hydrochlorothiazide Compound Tablet in Mild to Moderate Essential Hypertensive Patients Who Did Not Reach Goal with Olmesartan

[A Randomized, Double-Blind, Double-Dummy Study Comparing a Fixed Dose Combination of Telmisartan 80 Mg Plus Hydrochlorothiazide 12.5 Mg to Telmisartan 80 Mg in Chinese Hypertensive Patients Who Failed to Respond Adequately to Telmisartan 80 Mg].

Therapeutic Efficacy of Valsartan and Valsartan/hctz in Mild to Moderate Hypertensive Patients

The Clinical Efficacy and Safety of Valsartan in Treatment of Patients with Essential Hypertensive

Phase III randomized clinical trial of efficacy and safety of amlodipine and candesartan cilexetil combination for hypertension treatment

Aliskiren Therapy in Hypertension and Cardiovascular Disease: a Systematic Review and a Meta-Analysis

Effects of Compound Valsartan in Patients with Mild to Moderate Essential Hypertension

Clinical Observation on efficacy and safety of Telmisartan hydrochlorothiazide and Telmisartan in patients with Mild to Moderate Essential hypertension

Efficacy and Safety of Sacubitril/Allisartan for the Treatment of Primary Hypertension

Efficacy and Safety of Olmesartan Medoxomil-Amlodipine Besylate Tablet in Chinese Patients with Essential Hypertension: A Prospective, Single-Arm, Multi-Center, Real-World Study

A18728 Combination of Amlodipine with Diuretics or Telmisartan in High-risk Hypertensive Patients

Amlodipine/valsartan 5/160mg Versus Valsartan 160mg in Chinese Hypertensives

G-002 AMLODIPINE/VALSARTAN 5/160 MG VERSUS VALSARTAN 160 MG IN PREDOMINANTLY CHINESE PATIENTS WITH STAGE 1 OR 2 ESSENTIAL HYPERTENSION NOT ADEQUATELY CONTROLLED ON VALSARTAN 160 MG MONOTHERAPY

Effect of combining valsartan and amlodipine in the treatment of type 2 diabetes mellitus complicated by hypertension

Short-term therapeutic effect and safety of combined benazepril and lercanidipine for mild-moderate hypertension

Candesartan Versus Imidapril in Hypertension: a Randomised Study to Assess Effects of Anti-At1 Receptor Autoantibodies.

Effect on Blood Pressure Control of Switching from Valsartan Monotherapy to Losartan/hydrochlorothiazide in Asian Patients with Hypertension: Results of a Multicentre Open-Label Trial

[Efficacy and Safety of Olmesartan Medoxomil Versus Losartan Potassium in Chinese Patients with Mild to Moderate Essential Hypertension].

Efficacy and Safety of Valsartan/Amlodipine Single-Pill Combination in 11,422 Chinese Patients with Hypertension: an Observational Study

A Comparison of Initial Treatment with Losartan/hctz Versus Losartan Monotherapy in Chinese Patients with Mild to Moderate Essential Hypertension.